<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01184820</url>
  </required_header>
  <id_info>
    <org_study_id>13401</org_study_id>
    <nct_id>NCT01184820</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration</brief_title>
  <official_title>An Open-label Phase 1 Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration in Two Cohorts of Previously Treated Male Subjects With Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the pharmacokinetics (PK) of BAY94-9027(the test&#xD;
      drug). Pharmacokinetics means that we will measure how well the study drug corrects the&#xD;
      factor VIII levels in your blood and how long it takes for the levels to fall back to your&#xD;
      baseline level. The study is also designed to determine if the pharmacokinetics of BAY94-9027&#xD;
      change following repeat dosing over 8 weeks, determine if BAY94-9027 is safe, tolerable, and&#xD;
      effective for the treatment of severe hemophilia A and define the appropriate dose of&#xD;
      BAY94-9027. Two doses of BAY94-9027 will be studied.&#xD;
&#xD;
      The first 8 subjects enrolled in the study (cohort 1) will receive a low dose (25 IU/kg) and&#xD;
      will be treated 2 days a week for 8 weeks (total of 16 doses). The second 8 subjects (cohort&#xD;
      2) will receive a higher dose and will be treated 1 day a week for 8 weeks (total 8 doses).&#xD;
      All subjects will receive a single dose of rFVIII (Bayer Kogenate FS) to determine the PK by&#xD;
      measuring blood levels for 2 days before they start the study drug BAY94-9027. Factor VIII&#xD;
      blood levels for BAY94-9027 will be measured for 7 days after the first and last dose to see&#xD;
      describe the PK. Safety &amp; tolerability assessment include vital signs, coagulation and&#xD;
      hematological parameter, clinical chemistry, measurement of FVIII inhibitor and polyethylene&#xD;
      glycol (PEG) antibodies will be done during the course of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 13, 2010</start_date>
  <completion_date type="Actual">October 10, 2011</completion_date>
  <primary_completion_date type="Actual">October 10, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by measuring immunogenicity</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Antibodies to FVIII, polyethylene glycol (PEG) and BAY94-9027</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events collection</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration vs time curve from time 0 to the last data point (AUC0-tlast)</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration vs time curve from zero to infinity after single (first) dose (AUC0-inf)</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum drug concentration in plasma (Cmax)</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life associated with the terminal slope (t1/2)</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum drug concentration in plasma after single (first) dose (Tmax)</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total body clearance (CL)</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Total body clearance of drug from plasma (volume/time) or (volume/time/body weight) or ((volume/time)*(1.73/body surface area)) calculated after intravenous administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution at steady state (Vss)</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Based on the chromogenic, one-stage and PEG capture assays</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incremental recovery of FVIII</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Recovery was assessed using two different assays (chromogenic and one-stage assay)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)</intervention_name>
    <description>Single dose of Kogenate FS and 16 doses of BAY94-9027 given 2 times a week for 8 weeks. Both drugs to be given intravenously.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))</intervention_name>
    <description>Single dose of Kogenate FS and 9 doses of BAY94-9027 given once a week for 8 weeks. Both drugs to be given intravenously.</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male subjects with severe hemophilia A (documented plasma baseline Factor VIII level&#xD;
             &lt;1 %)&#xD;
&#xD;
          -  &gt;/= 18 but &lt;/= 65 years of age&#xD;
&#xD;
          -  Previously treated with Factor VIII concentrate(s) for a minimum of 150 exposure days&#xD;
             (as supported by the subject's medical history)&#xD;
&#xD;
          -  Immunocompetent with a CD4+ lymphocyte count &gt; 400/mm³&#xD;
&#xD;
          -  Signed informed consent from subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented history of inhibitor to Factor VIII with a titer &gt;/= 0.6 BU (Biological&#xD;
             Unit), by the Nijmegen modified assay. However, subjects with a maximum historical&#xD;
             titer of &lt;/= 1.0 BU with the classical Bethesda assay on a single measurement but with&#xD;
             at least 3 subsequent successive negative results (&lt; 0.6 BU) thereafter are eligible.&#xD;
&#xD;
          -  Unable to stop Factor VIII treatment to complete a minimum 72 hour washout&#xD;
&#xD;
          -  Current evidence of inhibitor to Factor VIII with a titer &gt;/= 0.6 BU, measured at the&#xD;
             time of screening&#xD;
&#xD;
          -  Abnormal renal function (serum creatinine &gt; 1.5 times the upper limit of the normal&#xD;
             range)&#xD;
&#xD;
          -  Total bilirubin &gt; 1.5 times the upper limit of the normal range&#xD;
&#xD;
          -  Active hepatic disease (alanine aminotransferase (ALT) and aspartate aminotransferase&#xD;
             (AST) levels &gt; 2 times the upper limit of the normal range)&#xD;
&#xD;
          -  Any concomitant coagulation disorder other than hemophilia A (including lupus&#xD;
             anticoagulant)&#xD;
&#xD;
          -  Platelet count &lt; 100,000/mm³&#xD;
&#xD;
          -  Within the last 3 months prior to study entry or during the study will be treated with&#xD;
             an immunomodulating drug other than anti-retroviral chemotherapy (e.g., a interferon,&#xD;
             steroids, rituximab, etc)&#xD;
&#xD;
          -  Any subject who requires major surgery during study period. Minor procedures may be&#xD;
             approved if discussed in advance with the medical expert.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115-6195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014 Apr;12(4):488-96.</citation>
    <PMID>24843882</PMID>
  </results_reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 13, 2010</study_first_submitted>
  <study_first_submitted_qc>August 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2010</study_first_posted>
  <last_update_submitted>September 6, 2018</last_update_submitted>
  <last_update_submitted_qc>September 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

